Seroxat Spitzer suit - part of industry wide agenda

Kevin Scotcher, an analyst at SG Securities, said the attorney general has a "much bigger agenda". Mr Scotcher said: "The question is, 'are consumers and doctors in possession of sufficient knowledge?' GSK pays for trials and has control over whether they are published or not. These trials are then used to sell a drug. His lawsuit is exploring something that will lead him to address conflicts of interests across the spectrum. The FDA is financed by the drug industry, for instance."




The Spitzer case will be examined to see if it sets a legal precedent - and GSK's decision to publish the trials will spark a debate over whether it, too, raises the ethical bar on publication.

http://webcache.googleusercontent.com/search?q=cache:hAQY4DjCquEJ:www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html+GSK+fights+Seroxat+claims&cd=1&hl=en&ct=clnk&gl=uk

extracted from -
 
GSK fights back in battle with Spitzer over Seroxat

http://www.independent.co.uk/life-style/health-and-families/health-news/gsk-fights-back-in-battle-with-spitzer-over-seroxat-731788.html